AstraZeneca, however, said that a lab study of Evusheld, the company’s coronavirus antibody cocktail, found that the treatment “retained neutralizing activity” against omicron. The study, conducted by independent investigators with the Food and Drug Administration, adds to “the growing body of preclinical evidence demonstrating that Evusheld retains activity against all tested variants of concern to date,” according to AstraZeneca.
Regeneron and AstraZeneca give mixed results on potency of coronavirus antibody cocktails against omicron – The Washington Post
